Sarepta Therapeutics (NASDAQ: SRPT) recently received a number of ratings updates from brokerages and research firms:

  • 8/4/2017 – Sarepta Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/2/2017 – Sarepta Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Sarepta reported encouraging Q2 results, beating estimates on both counts. The company also raised its revenue guidance for 2017. Sarepta received a huge boost with the FDA approval of Exondys 51, the first DMD treatment to gain approval in the U.S. Also, a marketing application is under review in the EU, which, if approved, should augment sales. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, Exondys 51’s commercial launch has been slower than expected due to slow patient starts and reimbursement hurdles. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. Meanwhile, the competitive RNA-based treatment market is a threat.”
  • 7/27/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
  • 7/24/2017 – Sarepta Therapeutics had its price target raised by analysts at Janney Montgomery Scott from $65.00 to $73.00. They now have a “fair value” rating on the stock.
  • 7/21/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $96.00 price target on the stock, down previously from $102.00.
  • 7/20/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $69.00 price target on the stock, up previously from $62.00.
  • 7/20/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc..
  • 7/20/2017 – Sarepta Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $60.00 to $64.00. They now have an “outperform” rating on the stock.
  • 7/20/2017 – Sarepta Therapeutics had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $33.00 price target on the stock, up previously from $31.00.
  • 7/20/2017 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $50.00 price target on the stock.
  • 7/18/2017 – Sarepta Therapeutics was given a new $64.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 7/18/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $60.00 price target on the stock, up previously from $52.00.
  • 7/17/2017 – Sarepta Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Sarepta has received a huge boost with the FDA approval of Exondys 51, the first DMD treatment to gain approval in the U.S. Also, a marketing application is under review in the EU, which if approved, should augment sales. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Sarepta’s shares have outperformed the industry in the last one year. However, Exondys 51’s commercial launch has been slower than expected due to slow patient starts and reimbursement hurdles. However, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. Meanwhile, competition in the RNA-based treatment market remains a threat. Estimates have remained mostly stable ahead of the Q2 results. Sarepta has a mixed record of earnings surprises in the recent quarters.”
  • 7/12/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $102.00 price target on the stock.
  • 7/3/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 6/30/2017 – Sarepta Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/30/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $64.00 price target on the stock.
  • 6/30/2017 – Sarepta Therapeutics had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
  • 6/23/2017 – Sarepta Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/22/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $60.00 price target on the stock.

Sarepta Therapeutics, Inc. (SRPT) opened at 37.97 on Thursday. The stock’s 50 day moving average is $36.90 and its 200 day moving average is $32.75. The firm’s market cap is $2.44 billion. Sarepta Therapeutics, Inc. has a 52 week low of $24.27 and a 52 week high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The business’s revenue for the quarter was up 350000.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.19) EPS. Equities research analysts expect that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current year.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram acquired 47,058 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were acquired at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the completion of the transaction, the chief executive officer now directly owns 382,058 shares in the company, valued at approximately $16,237,465. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Alexander Cumbo sold 5,918 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the sale, the senior vice president now directly owns 22,793 shares in the company, valued at approximately $934,513. The disclosure for this sale can be found here. In the last three months, insiders sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is currently owned by insiders.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.